Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Castellano

Showing results (181-190 of 266) with videos related to

Pageof 27
Sort By:
British Journal of Cancer|December 15, 2023
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)Albert Font, Begona Mellado, Miguel A Climent, et al.
Lancet (London, England)|November 8, 2011
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialBrian I Rini, Bernard Escudier, Piotr Tomczak, et al.
The Lancet. Oncology|September 14, 2020
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 studyKarim Fizazi, Gero Kramer, Jean-Christophe Eymard, et al.
The Journal of Urology|September 16, 2020
Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial CarcinomaXiao X Wei, Lillian Werner, Min Y Teo, et al.
European Urology Focus|June 5, 2024
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract CarcinomaCora N Sternberg, Yohann Loriot, Ernest Choy, et al.
Lancet (London, England)|September 18, 2024
<sup>177</sup>Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trialMichael J Morris, Daniel Castellano, Ken Herrmann, et al.
Future Oncology (London, England)|December 14, 2017
Radium-223 international early access program: results from the Spanish subsetJoan Carles, Mª José Méndez, Álvaro Pinto, et al.
International Journal of Cancer|July 24, 2019
PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinomaJuan M Roldan-Romero, Benoit Beuselinck, María Santos, et al.
Oncoimmunology|December 19, 2024
Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancerCarmen G Cañizo, Félix Guerrero-Ramos, Mercedes Perez Escavy, et al.
Cancer Research|September 26, 2014
In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancerMirentxu Santos, Mónica Martínez-Fernández, Marta Dueñas, et al.
Pageof 27

Showing results (181-190 of 266) with videos related to

Sort By:
Pageof 27
British Journal of Cancer|December 15, 2023
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)Albert Font, Begona Mellado, Miguel A Climent, et al.
Lancet (London, England)|November 8, 2011
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialBrian I Rini, Bernard Escudier, Piotr Tomczak, et al.
The Lancet. Oncology|September 14, 2020
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 studyKarim Fizazi, Gero Kramer, Jean-Christophe Eymard, et al.
The Journal of Urology|September 16, 2020
Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial CarcinomaXiao X Wei, Lillian Werner, Min Y Teo, et al.
European Urology Focus|June 5, 2024
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract CarcinomaCora N Sternberg, Yohann Loriot, Ernest Choy, et al.
Lancet (London, England)|September 18, 2024
<sup>177</sup>Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trialMichael J Morris, Daniel Castellano, Ken Herrmann, et al.
Future Oncology (London, England)|December 14, 2017
Radium-223 international early access program: results from the Spanish subsetJoan Carles, Mª José Méndez, Álvaro Pinto, et al.
International Journal of Cancer|July 24, 2019
PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinomaJuan M Roldan-Romero, Benoit Beuselinck, María Santos, et al.
Oncoimmunology|December 19, 2024
Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancerCarmen G Cañizo, Félix Guerrero-Ramos, Mercedes Perez Escavy, et al.
Cancer Research|September 26, 2014
In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancerMirentxu Santos, Mónica Martínez-Fernández, Marta Dueñas, et al.
Pageof 27